Novartis AG (NYSE:NVS) – Analysts at Jefferies Group issued their Q3 2016 earnings per share (EPS) estimates for shares of Novartis AG in a research note issued to investors on Thursday. Jefferies Group analyst J. Holford expects that the brokerage will earn $1.20 per share for the quarter. Jefferies Group also issued estimates for Novartis AG’s FY2018 earnings at $6.19 EPS, FY2019 earnings at $6.81 EPS and FY2020 earnings at $7.58 EPS.
NVS has been the topic of several other reports. Zacks Investment Research cut shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Wednesday, September 21st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a research note on Tuesday, September 13th. Argus reaffirmed a “hold” rating on shares of Novartis AG in a research note on Thursday, August 25th. Chardan Capital reduced their price objective on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, October 10th. Finally, Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 12th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Novartis AG currently has a consensus rating of “Hold” and a consensus target price of $91.33.
Novartis AG (NYSE:NVS) opened at 76.09 on Friday. The stock has a market capitalization of $181.19 billion, a PE ratio of 27.17 and a beta of 0.57. Novartis AG has a 12-month low of $69.90 and a 12-month high of $94.63. The stock’s 50 day moving average is $79.33 and its 200 day moving average is $78.96.
Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.18 by $0.05. Novartis AG had a net margin of 13.84% and a return on equity of 15.33%. The business had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same period in the previous year, the company posted $1.25 EPS.
Several large investors have recently modified their holdings of the company. Integrated Investment Consultants LLC raised its stake in shares of Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the last quarter. Whitnell & Co. raised its stake in shares of Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares during the last quarter. Iowa State Bank bought a new stake in shares of Novartis AG during the second quarter worth approximately $122,000. M&R Capital Management Inc. bought a new stake in shares of Novartis AG during the second quarter worth approximately $122,000. Finally, WFG Advisors LP raised its stake in shares of Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the last quarter. Institutional investors and hedge funds own 9.78% of the company’s stock.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.